193 related articles for article (PubMed ID: 36114551)
1. The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review.
Wang X; Wang S; Yao S; Shi W; Ma K
J Ovarian Res; 2022 Sep; 15(1):104. PubMed ID: 36114551
[TBL] [Abstract][Full Text] [Related]
2. Clinico-pathological spectrum of primary ovarian malignant mixed mullerian tumors (OMMMT) from a tertiary cancer institute: A series of 27 cases.
Menon S; Deodhar K; Rekhi B; Dhake R; Gupta S; Ghosh J; Maheshwari A; Mahantshetty U; Shrivastva S; Budukh A; Tongaonkar HB; Kerkar R
Indian J Pathol Microbiol; 2013; 56(4):365-71. PubMed ID: 24441223
[TBL] [Abstract][Full Text] [Related]
3. Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT).
Barnholtz-Sloan JS; Morris R; Malone JM; Munkarah AR
Gynecol Oncol; 2004 May; 93(2):506-12. PubMed ID: 15099970
[TBL] [Abstract][Full Text] [Related]
4. Presence of a sarcomatous component outside the ovary is an adverse prognostic factor for primary ovarian malignant mixed mesodermal/mullerian tumors: a clinicopathologic study of 47 cases.
Kunkel J; Peng Y; Tao Y; Krigman H; Cao D
Am J Surg Pathol; 2012 Jun; 36(6):831-7. PubMed ID: 22588065
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
Kuhn W; Rutke S; Späthe K; Schmalfeldt B; Florack G; von Hundelshausen B; Pachyn D; Ulm K; Graeff H
Cancer; 2001 Nov; 92(10):2585-91. PubMed ID: 11745193
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic factors for survival of ovarian epithelial cancers: apropos of 287 cases].
Brun JL; Bouzigon E; Saurel J; Chêne G; Briex M; Brun G; Hocke C
Gynecol Obstet Fertil; 2000 Mar; 28(3):223-31. PubMed ID: 10786403
[TBL] [Abstract][Full Text] [Related]
7. Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma.
Signorelli M; Chiappa V; Minig L; Fruscio R; Perego P; Caspani G; Battistello M; Colombo N
Int J Gynecol Cancer; 2009 Aug; 19(6):1142-6. PubMed ID: 19820383
[TBL] [Abstract][Full Text] [Related]
8. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
9. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
10. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
[TBL] [Abstract][Full Text] [Related]
11. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
12. [Clinical characteristics and prognosis of epithelial ovarian cancer in young women].
Tang L; Zheng M; Xiong Y; Ding H; Liu FY
Ai Zheng; 2008 Sep; 27(9):951-5. PubMed ID: 18799034
[TBL] [Abstract][Full Text] [Related]
13. [Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors].
He Y; Wang Y; Ji C; Liu Y; Wu YM
Zhonghua Fu Chan Ke Za Zhi; 2022 May; 57(5):352-360. PubMed ID: 35658326
[No Abstract] [Full Text] [Related]
14. Primary peritoneal serous papillary carcinoma: a clinical and pathological study.
Liu Q; Lin JX; Shi QL; Wu B; Ma HH; Sun GQ
Pathol Oncol Res; 2011 Sep; 17(3):713-9. PubMed ID: 21647781
[TBL] [Abstract][Full Text] [Related]
15. Malignant mixed müllerian tumors of the ovary.
Wei CF; Hwang SH; Ho CM; Shih BY; Chien TY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Apr; 63(4):344-8. PubMed ID: 10820916
[TBL] [Abstract][Full Text] [Related]
16. Primary Ovarian Malignant Mixed Mullerian Tumour: A Case Report and Brief Review of Literature.
Uçar MG; Çakir T; Ilhan TT; Karabagli P; Çelik Ç
J Clin Diagn Res; 2016 Mar; 10(3):QD04-6. PubMed ID: 27134951
[TBL] [Abstract][Full Text] [Related]
17. Malignant mixed Mullerian tumor of the ovary with two cases and review of the literature.
Duman BB; Kara IO; Günaldi M; Ercolak V
Arch Gynecol Obstet; 2011 Jun; 283(6):1363-8. PubMed ID: 21298439
[TBL] [Abstract][Full Text] [Related]
18. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
19. Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?
Heinzelmann-Schwarz V; Kind AB; Vetter M; Russell K; Omar S; Schoetzau A; Hoeck K; Fink D; Friedlander ML; Hacker NF
J Cancer Res Clin Oncol; 2020 Mar; 146(3):695-704. PubMed ID: 31993743
[TBL] [Abstract][Full Text] [Related]
20. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
Sood AK; Sorosky JI; Gelder MS; Buller RE; Anderson B; Wilkinson EJ; Benda JA; Morgan LS
Cancer; 1998 May; 82(9):1731-7. PubMed ID: 9576296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
